Produits et services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, genetic, psychologic, and psychiatric diseases and disorders Consultancy in the field of the medical treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; Consultancy in the field of the medical diagnosis of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; Health care services, namely, providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; Health care services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Abrégé

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 211/58 - Atomes d'azote liés en position 4
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

M4 positive allosteric modulators are disclosed which having a formula or a pharmaceutically acceptable salt or pharmaceutically acceptable salt hydrate or deuterated analog thereof. These compounds may be used for the therapeutic and/or prophylactic treatment of N14mediated diseases or disorders, such as Alzheimer's disease, schizophrenia, psychosis, Parkinson's disease, pain, addiction and Huntington's disease.

Classes IPC  ?

• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• C07D 487/02 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient deux hétérocycles
• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/33 - Composés hétérocycliques

Abrégé

M4 positive allosterie modulators of compound of the formula wherein R1 is a 4- or 5-membered heterocyclic ring, each of which may unsubstituted or substituted by one or more substituents, and which ring contains 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; R2 is a C1-C6 alkyl group; A is a 4- or 5-membered heterocyclic ring, each of which may be unsubstituted or substituted by one or more substituents, and which ring contains 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; R3 is a hydrogen atom or a C1-C6 alkyl group; and Ar is a 5-10 membered heterocyclic, aromatic or heteroaromatic monocyclic or bicyclic ring.

Classes IPC  ?

• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/33 - Composés hétérocycliques

Produits et services

Pharmaceutical preparations for the treatment of Prader-Willi syndrome (PWS) and related disorders; Pharmaceutical preparations for the treatment of neurodevelopmental and metabolic disorders

Produits et services

Pharmaceutical preparations for the treatment of Prader-Willi syndrome (PWS) and related disorders; Pharmaceutical preparations for the treatment of neurodevelopmental and metabolic disorders

Abrégé

2A2A.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61P 25/16 - Antiparkinsoniens
• A61P 25/24 - Antidépresseurs
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

Classes IPC  ?

• C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile

Produits et services

Promoting awareness of patient support offerings for neurodegenerative diseases and disorders and dementia; business administrative services for medical referrals Downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Printed publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment; printed questionnaires on medical issues Educational services, namely, providing educational programs in the nature of classes, seminars, and workshops about neurodegenerative diseases and disorders and dementia and diagnosis, identification, management, treatment, and patient support options for these conditions; multimedia educational services in the nature of recording and production services in the fields of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management distributed via various platforms across multiple forms of transmission media; providing on-line newsletters in the field of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management; online non-downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Testing, inspection, research, and development of diagnostic tests and questionnaires for symptoms of dementia-related psychosis, including hallucinations and delusions associated with dementia-related psychosis Medical consulting with respect to neurodegenerative diseases and disorders and dementia, including dementia-related psychosis and their identification and treatment; providing medical online information for health care providers and patients in the field of neurodegenerative diseases and disorders and dementia; medical informational support services, namely, providing medical information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients and healthcare professionals all related to neurodegenerative diseases and disorders and dementia

Produits et services

Downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Printed publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment; printed questionnaires on medical issues Promoting awareness of patient support offerings for neurodegenerative diseases and disorders and dementia; business administrative services for medical referrals Educational services, namely, providing educational programs in the nature of classes, seminars, and workshops about neurodegenerative diseases and disorders and dementia and diagnosis, identification, management, treatment, and patient support options for these conditions; multimedia educational services in the nature of recording and production services in the fields of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management distributed via various platforms across multiple forms of transmission media; providing on-line newsletters in the field of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management; online non-downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Testing, inspection, research, and development of diagnostic tests and questionnaires for symptoms of dementia-related psychosis, including hallucinations and delusions associated with dementia-related psychosis Medical consulting with respect to neurodegenerative diseases and disorders and dementia, including dementia-related psychosis and their identification and treatment; providing medical online information for health care providers and patients in the field of neurodegenerative diseases and disorders and dementia; medical informational support services, namely, providing medical information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients and healthcare professionals all related to neurodegenerative diseases and disorders and dementia

Produits et services

(1) Printed publications, namely, pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. (1) Promoting public awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders. (2) Medical referrals (3) Providing education information and instruction to adults, children, and parents of children with neurologic, genetic, psychologic, and psychiatric diseases and disorders; online electronic publishing of pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. (4) Hosting an online community website (5) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders; providing online information for health care providers, caregivers, patients, and families of patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, families of patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Produits et services

Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; administrative services for medical referrals. Educational services, namely, providing educational information and instruction to adults, children, and parents of children with neurologic, genetic, psychologic, and psychiatric diseases and disorders; publishing of electronic publications and printed matter, namely, pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders; providing online information for health care providers, caregivers, patients, and families of patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, families of patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; Providing an online community website featuring shared communications between community members interested in sharing medical information and experiences in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Produits et services

Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; administrative services for medical referrals. Educational services, namely, providing educational information and instruction to adults, children, and parents of children with neurologic, genetic, psychologic, and psychiatric diseases and disorders; publishing of electronic publications and printed matter, namely, pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders; providing online information for health care providers, caregivers, patients, and families of patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, families of patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; Hosting an online community website featuring shared communications between community members interested in sharing medical information and experiences in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; administrative services for medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Produits et services

Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support. Promoting awareness of patient support offerings for neurologic, metabolic, rare, and genetic diseases and disorders; promoting awareness of patient support offerings for pain associated with neurologic, metabolic, rare, and genetic diseases and disorders; business administration of reimbursement and medical benefit information for neurologic, metabolic, rare, and genetic conditions and their treatment; business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, metabolic, rare, and genetic conditions; business administrative services for medical referrals. Providing financial information regarding medical benefits and reimbursements available for medical expenses related thereto via a website; insurance services, namely, benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders. Educational services, namely, conducting educational programs in the fields of neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions. Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services. Medical consulting in the fields of neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, metabolic and genetic diseases and disorders.

Produits et services

Pharmaceuticals preparations for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders.

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders.

Abrégé

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R1, R2, R3, R4, R5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled receptor 88 (GPR88). Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases mediated by GPR88, including Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, Alzheimer's disease, and Attention Deficit Hyperactivity Disorder (ADHD). Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R1, R2, R3, R4, R5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled receptor 88 (GPR88). Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases mediated by GPR88, including Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, Alzheimer's disease, and Attention Deficit Hyperactivity Disorder (ADHD).

Classes IPC  ?

• C07D 215/08 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle avec l'atome d'azote du cycle acylé
• C07C 235/22 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné étant acyclique et saturé ayant au moins l'un des atomes d'oxygène liés par des liaisons simples, lié de plus à un atome de carbone d'un cycle aromatique à six chaînons, p. ex. phénoxyacétamides ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons
• C07C 235/24 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné étant acyclique et saturé ayant au moins l'un des atomes d'oxygène liés par des liaisons simples, lié de plus à un atome de carbone d'un cycle aromatique à six chaînons, p. ex. phénoxyacétamides ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 237/40 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons non condensé du squelette carboné ayant l'atome d'azote du groupe carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 237/42 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons non condensé du squelette carboné ayant des atomes d'azote de groupes amino liés au squelette carboné de la partie acide, en outre acylés
• C07C 255/54 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné contenant des groupes cyano et des groupes hydroxy éthérifiés liés au squelette carboné
• C07C 317/32 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné
• C07D 209/12 - Radicaux substitués par des atomes d'oxygène
• C07D 213/56 - Amides
• C07D 213/64 - Un atome d'oxygène lié en position 2 ou 6
• C07D 213/74 - Radicaux amino ou imino substitués par des radicaux hydrocarbonés ou par des radicaux hydrocarbonés substitués
• C07D 239/34 - Un atome d'oxygène
• C07D 239/42 - Un atome d'azote
• C07D 265/30 - Oxazines-1, 4Oxazines-1, 4 hydrogénées non condensées avec d'autres cycles
• C07D 295/135 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
• C07D 317/58 - Radicaux substitués par des atomes d'azote
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Produits et services

(1) Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support. (1) Promoting awareness of patient support offerings for neurologic, metabolic, rare, and genetic diseases and disorders; promoting awareness of patient support offerings for pain associated with neurologic, metabolic, rare, and genetic diseases and disorders; business administration of reimbursement and medical benefit information for neurologic, metabolic, rare, and genetic conditions and their treatment; business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, metabolic, rare, and genetic conditions; business administrative services for medical referrals. (2) Providing financial information regarding medical benefits and reimbursements available for medical expenses related thereto via a website; insurance services, namely, benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders. (3) Educational services, namely, conducting educational programs in the fields of neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions. (4) Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services. (5) Medical consulting in the fields of neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, metabolic and genetic diseases and disorders.

Abrégé

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07C 59/255 - Acide tartrique
• C07D 211/58 - Atomes d'azote liés en position 4

Abrégé

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more free/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Classes IPC  ?

• A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
• A61K 9/08 - Solutions
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/38 - CelluloseSes dérivés

Abrégé

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

Classes IPC  ?

• C07C 233/11 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués avec des atomes de carbone de groupes carboxamide liés à des atomes de carbone d'un squelette carboné non saturé contenant des cycles aromatiques à six chaînons
• C07D 213/56 - Amides
• C07D 231/12 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide

Abrégé

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

Classes IPC  ?

• C07D 213/56 - Amides
• C07D 213/65 - Un atome d'oxygène lié en position 3 ou 5
• C07D 233/16 - Radicaux substitués par des atomes d'azote
• C07D 305/08 - Composés hétérocycliques contenant des cycles à quatre chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes du cycle
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• C07D 333/24 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile

Produits et services

Pharmaceutical products and preparations for the treatment of Prader-Willi syndrome (PWS) and related metabolic and neurodevelopmental disorders; pharmaceutical products and preparations for the treatment of neurodevelopmental and metabolic disorders

Produits et services

Pharmaceutical products and preparations for the treatment of Prader-Willi syndrome (PWS) and related metabolic and neurodevelopmental disorders; pharmaceutical products and preparations for the treatment of neurodevelopmental and metabolic disorders

Produits et services

Pharmaceutical products and preparations for the treatment of Prader-Willi syndrome (PWS) and related metabolic and neurodevelopmental disorders; pharmaceutical products and preparations for the treatment of neurodevelopmental and metabolic disorders

Abrégé

The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

Classes IPC  ?

• A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods. The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Classes IPC  ?

• C07C 225/20 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du squelette carboné
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Abrégé

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

Classes IPC  ?

• C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile

Abrégé

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Classes IPC  ?

• A61K 38/12 - Peptides cycliques
• A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 9/08 - Solutions

Abrégé

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

Classes IPC  ?

• A01N 43/64 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec trois atomes d'azote comme uniques hétéro-atomes du cycle
• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61K 31/33 - Composés hétérocycliques
• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

Methods of treating, ameliorating, and/or preventing osteoarthritic pain are provided. The methods include administering to an individual a therapeutically effective amount of a compound of Formula I (Compound 1). The method can be used to treat, ameliorate, and/or prevent osteoarthritic pain, as well as other symptoms, arising from osteoarthritis. Compound 1 can be formulated into many suitable dosage forms, including oral dosage forms such as tablets.

Classes IPC  ?

• A61K 31/426 - 1,3-Thiazoles
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Classes IPC  ?

• C07C 225/20 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du squelette carboné
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Produits et services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, namely, seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, chronic pain, glaucoma, Rett syndrome, autism spectrum disorders, Fragile X Syndrome (FXS), Angelman Syndrome, Tuberous Sclerosis Complex, Phelan McDermid Syndrome, CDKL5 mutations, MECP2 mutations, autism, FOXG1 Syndrome, Infantile spasm, KIF1A syndrome, Syngap1 disorder, Dravet syndrome, Mowat-Wilson syndrome, MECP2 duplication, 15q11q13 duplication, Pitt-Hopkins syndrome, Prader Willi syndrome, Ischemic injury, and Down syndrome. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders, consultation related thereto; research in the field of industrial biotechnology and biomedical research, consultation related thereto; chemical analysis, biochemical analyses, analyses in the field of molecular biology, consultation related thereto; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs, consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Produits et services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, namely, seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, chronic pain, glaucoma, Rett syndrome, autism spectrum disorders, Fragile X Syndrome (FXS), Angelman Syndrome, Tuberous Sclerosis Complex, Phelan McDermid Syndrome, CDKL5 mutations, MECP2 mutations, autism, FOXG1 Syndrome, Infantile spasm, KIF1A syndrome, Syngap1 disorder, Dravet syndrome, Mowat-Wilson syndrome, MECP2 duplication, 15q11q13 duplication, Pitt-Hopkins syndrome, Prader Willi syndrome, Ischemic injury, and Down syndrome. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders, consultation related thereto; research in the field of industrial biotechnology and biomedical research, consultation related thereto; chemical analysis, biochemical analyses, analyses in the field of molecular biology, consultation related thereto; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs, consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Abrégé

Disclosed herein are methods of treating Rett syndrome comprising administering trofinetide to a subject in need thereof in which a dosage is provided that may reduce or avoid underexposure, e.g., in low body weight subjects, and/or provide other benefits.

Classes IPC  ?

• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The disclosure provides, in part, a method of treating a disorder in a patient in need of pimavanserin, the method comprising administering to the patient about 2 mg to about 80 mg of pimavanserin via, e.g., an enteral feeding tube, once daily, wherein pimavanserin is dissolved in, mixed with, or sparkled onto, e.g., about 5 mL to about 150 mL of, a liquid vehicle or soft food vehicle at ambient or cold temperature before the administration.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

The present disclosure relates generally to therapeutic use of pimavanserin or a pharmaceutical acceptable salt thereof. More specifically, the present disclosure provides methods for treating schizophrenia by administering pimavanserin or a pharmaceutical acceptable salt thereof as an adjunct therapy in a patient who has an inadequate response to another antipsychotic therapy.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Abrégé

Behavioral pharmacological data with the compound of formula (1), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that SHT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07D 211/58 - Atomes d'azote liés en position 4
• A61K 31/194 - Acides carboxyliques, p. ex. acide valproïque ayant plusieurs groupes carboxyle, p. ex. acides succinique, maléique ou phtalique
• C07C 59/255 - Acide tartrique
• A61K 9/20 - Pilules, pastilles ou comprimés

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Abrégé

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Classes IPC  ?

• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 47/38 - CelluloseSes dérivés

Abrégé

The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.

Classes IPC  ?

• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes

Abrégé

This disclosure provides, in part, a method of treating major depression, psychosis secondary to neurodegenerative disorders, or schizophrenia in a patient in need thereof, wherein the patient is currently taking a daily dose of an SSRI or an SNRI that prolongs the QT interval, comprising administering a daily dose of pimavanserin to the patient and continuing administering the SSRI or the SNRI, and wherein upon the administration of the pimavanserin, the QT interval of the patient does not significantly increase.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61P 25/24 - Antidépresseurs
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Abrégé

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Classes IPC  ?

• C07C 225/20 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du squelette carboné
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone

Abrégé

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Classes IPC  ?

• A61K 38/12 - Peptides cycliques
• A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 9/08 - Solutions

Produits et services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders namely seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; research in the field of industrial biotechnology and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related to medical testing, namely, in vitro and in vivo preclinical testing of potential drugs.

Produits et services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders namely seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; research in the field of industrial biotechnology and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related to medical testing, namely, in vitro and in vivo preclinical testing of potential drugs.

Produits et services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders namely seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; research in the field of industrial biotechnology and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related to medical testing, namely, in vitro and in vivo preclinical testing of potential drugs.

Abrégé

2 or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

Classes IPC  ?

• C07D 211/58 - Atomes d'azote liés en position 4
• C07D 211/98 - Atome d'azote

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs and consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs; and consultation related to all the foregoing services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs; and consultation related to all the foregoing services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs; and consultation related to all the foregoing services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs and consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; in vitro and in vivo preclinical testing of potential drugs; consultation related thereto. Medical testing.

Abrégé

Disclosed herein are methods of treating Rett syndrome comprising administering trofinetide to a subject in need thereof in which a dosage is provided that may reduce or avoid underexposure, e.g., in low body weight subjects, and/or provide other benefits.

Classes IPC  ?

• A61K 38/06 - Tripeptides
• A61K 31/401 - ProlineSes dérivés, p. ex. captopril
• C07K 5/08 - Tripeptides
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.

Classes IPC  ?

• C07D 211/58 - Atomes d'azote liés en position 4
• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 471/04 - Systèmes condensés en ortho

Abrégé

The disclosure provides, in part, a method of treating a disorder in a patient in need of pimavanserin, the method comprising administering to the patient about 2 mg to about 80 mg of pimavanserin via, e.g., an enteral feeding tube, once daily, wherein pimavanserin is dissolved in, mixed with, or sparkled onto, e.g., about 5 mL to about 150 mL of, a liquid vehicle or soft food vehicle at ambient or cold temperature before the administration.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present disclosure relates generally to therapeutic use of pimavanserin or a pharmaceutical acceptable salt thereof. More specifically, the present disclosure provides methods for treating schizophrenia by administering pimavanserin or a pharmaceutical acceptable salt thereof as an adjunct therapy in a patient who has an inadequate response to another antipsychotic therapy.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl

Produits et services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders, namely Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma (1) Scientific research in the field of neurologic, metabolic and genetic diseases and disorders; industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; in vitro and in vivo preclinical testing of potential drugs; medical consulting with respect to neurologic, metabolic, and genetic conditions and their treatment

Abrégé

The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

Classes IPC  ?

• A61K 38/12 - Peptides cycliques
• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/08 - Solutions

Abrégé

Provided herein are methods of making a thiazoline anti-hyperalgesic, Compound 1, and polymorphs thereof. The methods described herein use inexpensive reagents and are capable of providing Compound 1 in commercial-scale quantities. Also provided are pharmaceutical compositions of Compound 1 suitable for human administration.

Classes IPC  ?

• C07D 277/18 - Atomes d'azote

Produits et services

Downloadable electronic publications in the nature of brochures, pamphlets, reports, newsletters, articles, guidebooks, case studies and white papers in the field of neurologic, metabolic, and genetic diseases and disorders, patient support, and medical information regarding disease management Publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurologic, metabolic, and genetic diseases and disorders, patient support, and medical information regarding disease management Promoting awareness of patient support offerings for neurodegenerative diseases and disorders and dementia; Business administrative services for medical referrals Educational services, namely, providing educational programs about neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions; multimedia educational services in the nature of recording and production services in the fields of neurologic, metabolic, and genetic diseases and disorders, medical informational support services, and medical information regarding disease management; providing on-line newsletters in the field of neurologic, metabolic, and genetic diseases and disorders, medical informational support services, and medical information regarding disease management; providing online non-downloadable electronic publications in the nature of brochures, pamphlets, reports, newsletters, articles, guidebooks, case studies and white papers in the field of neurologic, metabolic, and genetic diseases and disorders, patient support, and medical information regarding disease management Medical consulting with respect to neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical informational support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals all related to neurologic, metabolic and genetic diseases and disorders

Abrégé

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 211/58 - Atomes d'azote liés en position 4
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
• A61K 31/13 - Amines, p. ex. amantadine

Abrégé

Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing NPI-NH score in a human with Alzheimer's Disease comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing agitated behavior or aggressive behavior in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/13 - Amines, p. ex. amantadine
• A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/473 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. acridines, phénantridines
• A61K 31/549 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame ayant plusieurs atomes d'azote dans le même cycle, p. ex. hydrochlorothiazide
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto

Produits et services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto

Abrégé

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 47/38 - CelluloseSes dérivés

Produits et services

Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto

Abrégé

2 or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

Classes IPC  ?

• C07D 211/58 - Atomes d'azote liés en position 4

Abrégé

2 or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

Classes IPC  ?

• C07D 211/58 - Atomes d'azote liés en position 4

Produits et services

Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Promoting awareness of patient support offerings for neurologic, metabolic, rare, and genetic diseases and disorders; promoting awareness of patient support offerings for pain associated with neurologic, metabolic, rare, and genetic diseases and disorders; business administration of reimbursement and medical benefit information for neurologic, metabolic, rare, and genetic conditions and their treatment; business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, metabolic, rare, and genetic conditions; Business administrative services for medical referrals Providing a website featuring financial information regarding medical benefits and reimbursements available for medical expenses related thereto; insurance services, namely, benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders Educational services, namely, conducting educational programs in the fields of neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions Medical consulting in the fields of neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, metabolic and genetic diseases and disorders

Abrégé

NNNNNNN'-(4-(2- methylpropyloxy)phenylmethyl)carbamide once daily, as well as methods for the treatment of a SSRI or SNRI- induced sexual dysfunction in a human subject.

Classes IPC  ?

• A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
• A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
• A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
• A61K 31/15 - Oximes (C=N-O-)Hydrazines ( N-N)Hydrazones (N-N=)
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 31/4525 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/24 - Antidépresseurs
• A61P 25/22 - Anxiolytiques
• A61P 15/10 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour l'impuissance

Produits et services

Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services

Abrégé

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Classes IPC  ?

• A61K 38/12 - Peptides cycliques
• A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 9/08 - Solutions

Abrégé

A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61P 25/24 - Antidépresseurs
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/16 - Antiparkinsoniens

Abrégé

A method for treating a impulse control disorder in a patient comprising administering to the patient an effective amount of pimavanserin or a pharmaceutical acceptable salt thereof.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique

Abrégé

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 47/38 - CelluloseSes dérivés

Abrégé

The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes

Abrégé

Provided herein are methods for assessing a patient's suicidality. Also provided herein are methods for including or excluding a patient from a clinical study group.

Classes IPC  ?

• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 25/16 - Antiparkinsoniens
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

Classes IPC  ?

• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61P 25/24 - Antidépresseurs
• A61P 25/16 - Antiparkinsoniens

Abrégé

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 47/38 - CelluloseSes dérivés

Abrégé

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl

Abrégé

The present disclosure relates to compounds according to Formula (I), treating diseases.

Classes IPC  ?

• C07D 451/06 - Atomes d'oxygène
• C07D 487/04 - Systèmes condensés en ortho
• C07D 487/08 - Systèmes pontés
• C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
• C07D 211/58 - Atomes d'azote liés en position 4
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 241/04 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
• C07D 207/08 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés, substitués par des hétéro-atomes, liés aux atomes de carbone du cycle
• C07D 211/44 - Atomes d'oxygène liés en position 4
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
• A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine